JP2016531138A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016531138A5 JP2016531138A5 JP2016538988A JP2016538988A JP2016531138A5 JP 2016531138 A5 JP2016531138 A5 JP 2016531138A5 JP 2016538988 A JP2016538988 A JP 2016538988A JP 2016538988 A JP2016538988 A JP 2016538988A JP 2016531138 A5 JP2016531138 A5 JP 2016531138A5
- Authority
- JP
- Japan
- Prior art keywords
- spray
- bendamustine
- solid dispersion
- dried solid
- dried
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007962 solid dispersion Substances 0.000 claims 15
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims 14
- 229960002707 bendamustine Drugs 0.000 claims 14
- 238000001035 drying Methods 0.000 claims 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 239000000243 solution Substances 0.000 claims 5
- 239000003125 aqueous solvent Substances 0.000 claims 4
- 238000007664 blowing Methods 0.000 claims 3
- 239000011261 inert gas Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000000843 powder Substances 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 239000007857 degradation product Substances 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims 2
- 229960001507 ibrutinib Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000006199 nebulizer Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000012467 final product Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 230000000877 morphologic effect Effects 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 230000000704 physical effect Effects 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361870609P | 2013-08-27 | 2013-08-27 | |
| US61/870,609 | 2013-08-27 | ||
| PCT/US2014/052341 WO2015031198A2 (en) | 2013-08-27 | 2014-08-22 | Bendamustine pharmaceutical compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016531138A JP2016531138A (ja) | 2016-10-06 |
| JP2016531138A5 true JP2016531138A5 (cg-RX-API-DMAC7.html) | 2017-09-28 |
| JP6571657B2 JP6571657B2 (ja) | 2019-09-04 |
Family
ID=52584085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016538988A Active JP6571657B2 (ja) | 2013-08-27 | 2014-08-22 | ベンダムスチンの薬学的組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (7) | US9849115B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3043648B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6571657B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN109953954A (cg-RX-API-DMAC7.html) |
| AU (5) | AU2014311570C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2922099C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2957541T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL244133A0 (cg-RX-API-DMAC7.html) |
| MX (2) | MX376522B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015031198A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201601645B (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6571657B2 (ja) | 2013-08-27 | 2019-09-04 | ボウドウリス バシリオス | ベンダムスチンの薬学的組成物 |
| CN106102722A (zh) * | 2014-03-13 | 2016-11-09 | V·沃道里斯 | 苯达莫司汀固体分散体和连续输液 |
| JP6937016B2 (ja) * | 2017-09-06 | 2021-09-22 | 東京理化器械株式会社 | 噴霧乾燥装置 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030203036A1 (en) * | 2000-03-17 | 2003-10-30 | Gordon Marc S. | Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients |
| CN1153570C (zh) * | 1997-12-31 | 2004-06-16 | 中外制药株式会社 | 制备依曲康唑口服制剂的方法及组合物 |
| SE0000773D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
| US20030105141A1 (en) | 2001-04-17 | 2003-06-05 | Ping Gao | Finely self-emulsifiable pharmaceutical composition |
| JP4644397B2 (ja) * | 2001-09-05 | 2011-03-02 | 信越化学工業株式会社 | 難溶性薬物を含む医薬用固形製剤の製造方法 |
| WO2003043603A1 (en) | 2001-11-20 | 2003-05-30 | Advanced Inhalation Research, Inc. | Particulate compositions for improving solubility of poorly soluble agents |
| US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| CN1887261A (zh) | 2006-07-25 | 2007-01-03 | 济南帅华医药科技有限公司 | 含苯达莫司汀的复方抗癌缓释注射剂 |
| CN1887269A (zh) * | 2006-07-25 | 2007-01-03 | 济南帅华医药科技有限公司 | 一种含苯达莫司汀及其增效剂的抗癌缓释注射剂 |
| DE102007009242A1 (de) * | 2007-02-22 | 2008-09-18 | Evonik Röhm Gmbh | Pellets mit magensaftresistenter Wirkstoff-Matix |
| US20090130198A1 (en) | 2007-11-21 | 2009-05-21 | Innopharmax Inc. | Pharmaceutical composition with enhanced bioavailability |
| AR072777A1 (es) | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
| JP5670335B2 (ja) | 2008-09-25 | 2015-02-18 | セファロン、インク． | ベンダムスチン液体製剤 |
| HRP20140204T1 (hr) | 2008-12-03 | 2014-04-11 | Astellas Deutschland Gmbh | Oralni oblici doziranja bendamustina |
| UA107186C2 (xx) * | 2008-12-03 | 2014-12-10 | Тверді форми дозування бендамустину | |
| RU2591804C2 (ru) * | 2009-02-25 | 2016-07-20 | Супратек Фарма, Инк. | Композиции бендамустина и циклополисахарида |
| US20100273730A1 (en) | 2009-04-27 | 2010-10-28 | Innopharmax, Inc. | Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof |
| CN102413816A (zh) * | 2009-04-28 | 2012-04-11 | 赛福伦公司 | 苯达莫司汀的口服制剂 |
| EP3895694A1 (en) | 2010-01-28 | 2021-10-20 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
| WO2011103150A2 (en) * | 2010-02-18 | 2011-08-25 | Cephalon, Inc. | Lyophilized preparations of bendamustine |
| JO3659B1 (ar) * | 2010-06-02 | 2020-08-27 | Astellas Deutschland Gmbh | أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية |
| EP2667868A4 (en) | 2011-01-25 | 2014-12-10 | Reddys Lab Ltd Dr | Benda MUSTIN FORMULATIONS |
| WO2013102920A1 (en) | 2011-11-18 | 2013-07-11 | Astron Research Limited | Stable lyophilized formulation of bendamustine |
| US9872873B2 (en) | 2012-02-06 | 2018-01-23 | Fresenius Kabi Oncology Limited | Process for preparing stable pharmaceutical compositions of compounds susceptible to hydrolysis |
| JP2015506989A (ja) * | 2012-02-14 | 2015-03-05 | イーグル・ファーマシューティカルズ・インコーポレーテッド | ベンダムスチン製剤 |
| DK2827862T3 (da) | 2012-03-20 | 2024-02-12 | Eagle Pharmaceuticals Inc | Formuleringer af bendamustin |
| EP2641592A1 (en) | 2012-03-23 | 2013-09-25 | Salmon Pharma GmbH | Pharmaceutical formulation comprising bendamustine |
| US20150140085A1 (en) | 2012-06-29 | 2015-05-21 | Principia Biopharma Inc. | Formulations comprising ibrutinib |
| JP6571657B2 (ja) | 2013-08-27 | 2019-09-04 | ボウドウリス バシリオス | ベンダムスチンの薬学的組成物 |
| CN106102722A (zh) | 2014-03-13 | 2016-11-09 | V·沃道里斯 | 苯达莫司汀固体分散体和连续输液 |
-
2014
- 2014-08-22 JP JP2016538988A patent/JP6571657B2/ja active Active
- 2014-08-22 US US14/466,765 patent/US9849115B2/en active Active
- 2014-08-22 WO PCT/US2014/052341 patent/WO2015031198A2/en not_active Ceased
- 2014-08-22 CN CN201910051265.7A patent/CN109953954A/zh active Pending
- 2014-08-22 MX MX2016002502A patent/MX376522B/es active IP Right Grant
- 2014-08-22 EP EP14840972.5A patent/EP3043648B1/en active Active
- 2014-08-22 CA CA2922099A patent/CA2922099C/en active Active
- 2014-08-22 ES ES14840972T patent/ES2957541T3/es active Active
- 2014-08-22 CN CN201480045199.8A patent/CN105491886B/zh active Active
- 2014-08-22 AU AU2014311570A patent/AU2014311570C1/en active Active
- 2014-10-20 US US14/519,079 patent/US9061011B1/en active Active
-
2016
- 2016-02-15 IL IL244133A patent/IL244133A0/en unknown
- 2016-02-25 MX MX2020006075A patent/MX2020006075A/es unknown
- 2016-03-09 ZA ZA2016/01645A patent/ZA201601645B/en unknown
-
2017
- 2017-11-16 US US15/815,578 patent/US10786486B2/en active Active
-
2018
- 2018-07-19 AU AU2018206777A patent/AU2018206777A1/en not_active Abandoned
-
2020
- 2020-08-21 US US16/999,908 patent/US20210008036A1/en not_active Abandoned
- 2020-12-08 AU AU2020286183A patent/AU2020286183A1/en not_active Abandoned
- 2020-12-10 AU AU2020286280A patent/AU2020286280A1/en not_active Abandoned
-
2021
- 2021-11-22 US US17/532,874 patent/US11701344B2/en active Active
-
2022
- 2022-11-02 AU AU2022263496A patent/AU2022263496A1/en not_active Abandoned
-
2023
- 2023-05-23 US US18/200,980 patent/US20230310381A1/en not_active Abandoned
-
2024
- 2024-05-16 US US18/665,804 patent/US20240299363A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105902496B (zh) | 一种纳米混悬液固体化过程的处理方法 | |
| KR101763195B1 (ko) | 건조 분말 반코마이신 조성물 및 관련 방법 | |
| JP2009530415A5 (cg-RX-API-DMAC7.html) | ||
| JP2015527395A5 (cg-RX-API-DMAC7.html) | ||
| NZ707328A (en) | Virus-containing formulation and use thereof | |
| JP2015509788A5 (cg-RX-API-DMAC7.html) | ||
| IL298998B2 (en) | Pharmaceutical formulations of a hif hydroxylase inhibitor | |
| AR093012A1 (es) | Composiciones farmaceuticas en polvo, activas, con enmascaramiento del sabor y procesos para su fabricacion | |
| CN105232488A (zh) | 一种含有利伐沙班的固体药物组合物 | |
| JP2021054870A (ja) | 肺送達用ラパマイシン粉末 | |
| JP2015515968A5 (cg-RX-API-DMAC7.html) | ||
| JP2016531138A5 (cg-RX-API-DMAC7.html) | ||
| MX2017004476A (es) | Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion. | |
| CN104587472A (zh) | 一种含纳米SiO2的包衣剂及其制备方法 | |
| ES2372983T3 (es) | Proceso para preparar formulaciones secadas por aspersión de tmc125. | |
| JP2010536837A5 (cg-RX-API-DMAC7.html) | ||
| CN105106152A (zh) | 一种盐酸决奈达隆组合物 | |
| JP2015120758A5 (cg-RX-API-DMAC7.html) | ||
| CN102178677B (zh) | 硝苯地平双层渗透泵药物组合物及其制备工艺 | |
| JP2017048174A (ja) | 化学的に安定な原薬含有被覆粒子を含む口腔内崩壊錠剤 | |
| CN103637984A (zh) | 一种黄芩苷纳米结晶及其制备方法 | |
| CN100522167C (zh) | 注射用帕洛诺司琼及其药物上可接受的盐的粉针制剂及其制备方法 | |
| WO2020111089A1 (ja) | 医薬組成物 | |
| CN108938580B (zh) | 盐酸帕罗西汀口崩片 | |
| CN105796498B (zh) | 一种粉末包衣叶酸及其制备方法 |